Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive f...

por Hayashi, Hidetoshi, Nakagawa, Kazuhiko
Publicado no J Thorac Dis (2016)

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer

por Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no Mol Clin Oncol (2017)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

por Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no Int J Mol Sci (2019)

Echinoderm microtubule‐associated protein‐like 4–anaplastic lymphoma kinase‐targeted therapy for advanced non‐small cell lung cancer: Molecular and clinical aspects

por Okamoto, Isamu, Nakagawa, Kazuhiko
Publicado no Cancer Sci (2012)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer

por Hayashi, Hidetoshi, Kurata, Takayasu, Nakagawa, Kazuhiko
Publicado em 2011

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib...

por Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko
Publicado em 2014

Clinical development of nintedanib for advanced non-small-cell lung cancer

por Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko
Publicado no Ther Clin Risk Manag (2015)

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

por Watanabe, Satomi, Hayashi, Hidetoshi, Nakagawa, Kazuhiko
Publicado no Ann Transl Med (2016)

A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group

por Haratani, Koji, Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no J Thorac Dis (2019)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?

por Haratani, Koji, Hayashi, Hidetoshi, Nakagawa, Kazuhiko
Publicado no BMC Med (2020)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?

por Kanemura, Hiroaki, Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no Transl Lung Cancer Res (2020)

Selection Pressure and Altered Hepatocellular Islands after a Single Injection of Aflatoxin B1

por Moore, Malcolm A., Nakagawa, Kazuhiko, Ishikawa, Takatoshi
Publicado no Jpn J Cancer Res (1988)

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lu...

por Okamoto, Isamu, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko, Fukuoka, Masahiro
Publicado em 2010

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

por Togashi, Yosuke, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Nishio, Kazuto
Publicado em 2014

A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer

por Takahama, Takayuki, Takeda, Masayuki, Nishina, Shinichi, Nakagawa, Kazuhiko
Publicado no BMC Res Notes (2015)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

por Takeda, Masayuki, Okamoto, Isamu, Nishimura, Yasumasa, Nakagawa, Kazuhiko
Publicado no Lung Cancer (Auckl) (2011)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

por Takeda, Masayuki, Sakai, Kazuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Publicado no Onco Targets Ther (2019)

Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14

por Kanemura, Hiroaki, Takeda, Masayuki, Shimizu, Shigeki, Nakagawa, Kazuhiko
Publicado no Thorac Cancer (2020)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevaciz...

por Takeda Masayuki, Okamoto Isamu, Yamanaka Takeharu, Nakagawa Kazuhiko, Nakanishi Yoichi
Publicado em 2012-08-01

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevaciz...

por Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, Nakanishi, Yoichi
Publicado em 2012